Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

• Status: Recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer and triple negative breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer and triple negative breast cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Phoenix Molecular Designs

Criteria

Inclusion Criteria:

1. Signed informed consent

2. Age ≥ 18 years

3. ECOG Performance Status ≤ 2

4. [Part 1 - Dose Escalation] Histologically or cytologically diagnosed metastatic breast cancer that has progressed on or after standard of care therapy and for which no standard of care therapy is available that would confer clinical benefit

5. [Part 2 - Dose Expansion] Histologically or cytologically diagnosed metastatic triple-negative breast cancer with <1% expression of ER and PR and negative for HER2 (either 0 or 1+ by IHC or IHC 2+ and fluorescence in situ hybridization (FISH) negative) from the time of initial diagnosis that has progressed on or after standard of care therapy and for which no standard of care therapy is available that would confer clinical benefit

6. [Part 1 - Dose Escalation] Evaluable or measurable disease by RECISTv1.1

7. [Part 2 - Dose Expansion] Measurable disease by RECISTv1.1

8. Adequate laboratory parameters including:

1. Absolute Neutrophil Count (ANC) ≥ 1500/mm^3

2. Platelets ≥ 100,000/mm^3

3. AST/SGOT ≤ 2.5 x ULN (≤ 5 x ULN if known liver involvement)

4. ALT/SGPT ≤ 2.5 x ULN (≤ 5 x ULN if known liver involvement)

5. Total bilirubin ≤ 1.5 x ULN (unless diagnosis of Gilbert's syndrome in which case < 3.0 times ULN)

6. Serum creatinine ≤ 1.5 x ULN or estimated GFR ≥ 60 mL/min

9. If residual treatment related toxicity from prior therapy:

1. Treatment related toxicity resolved to at least Grade 1 (alopecia excepted), or

2. Treatment related toxicity resolved to at least Grade 2 with prior approval of the Medical Monitor

10. Available archival or fresh tumor tissue (Formalin-fixed paraffin-embedded [FFPE])

11. [Females] The patient must be postmenopausal, surgically sterile, or agree to use adequate contraception (adequate as determined by the PI - may include abstinence) throughout the study and for a least 30 days following the last dose of PMD-026

12. [Males] The patient must be surgically sterile or must agree to use adequate contraception (adequate as determined by the PI - may include abstinence) throughout the study and for at least 30 days following the last dose of PMD-026

13. [Males] The patient must agree to refrain from donating sperm throughout the study and for at least 30 days following the last dose of PMD-026

14. [Females] If of childbearing potential, the patient must have a negative serum pregnancy test

Exclusion Criteria:

1. ≤ 14 days from prior chemotherapy, biological or investigational therapy

2. Use of any medications known to result in a prolongation of the QT/QTc interval

3. Use of any medication that is a strong inducer or substrate of cytochrome P450 3A

4. Use of any medications that is a substrate of BCRP

5. Use of any medication that is a substrate of MATE2K

6. ≤ 28 days from prior irradiation (including therapeutic radioisotopes such as strontium 89)

7. ≤ 7 days from limited field irradiation for palliation

8. ≤ 28 days from major surgical procedures

9. ≤ 7 days from minor surgical procedures (no waiting period required following central catheter placement)

10. Central nervous system metastases, unless appropriately treated and neurologically stable for ≥ 28 days

11. Known history of leptomeningeal metastases

12. Uncontrolled bacterial, viral, or fungal infection (s) requiring systemic therapy

13. Pregnant or currently breast-feeding

14. Known Hepatitis B or Hepatitis C infection

15. Known HIV-positive with CD4+ cell counts < 350 cells/uL

16. Known HIV-positive with a history of an AIDS-defining opportunistic infection

17. History of clinically significant cardiovascular abnormalities including:

1. Congestive heart failure (NYHA classification ≥ 3 in within 6 months of first dose of PMD-026

2. Unstable angina pectoris

3. Myocardial infarction within 12 months of study entry

4. Arrhythmias requiring continued treatment (controlled atrial fibrillation allowed)

5. QTcF interval > 460 msec (using Fridericia's formula)

18. Presence of active gastrointestinal disease or other condition that is expected to interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade ≥ 2, and malabsorption syndrome)

19. Inadequately controlled hypertension defined as systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg (patients with values above these levels must have their blood pressure controlled prior to starting treatment)

20. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment

21. Other known active cancer(s) likely to require treatment in the next year that would impact the assessment of any study endpoints

22. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol